CIBMTR real-world data: about one-third of multiple myeloma patients receiving cilta-cel are frail, with 12-month PFS of 62.7% and OS of 72.8% and doubled ICANS risk
Using Center for International Blood and Marrow Transplant Research registry data, this study evaluated 541 patients with relapsed/refractory multiple myeloma who received commercial cilta-cel between March 2022 and December 2023 and found that 183 (33.8%) were frail by an adapted simplified frailty score; overall response rates were comparable (82.8% vs. 88.5%), but frail patients had worse 12-month progression-free survival (62.7% vs. 75.9%) and overall survival (72.8% vs. 90.4%) and more any-grade ICANS (32.2% vs. 17.6%), with frailty independently predicting worse PFS (HR 1.67), OS (HR 2.46), and any-grade ICANS (OR 2.01) on multivariable analysis.